[What’s new in dialysis in 2025?].
Cardiovascular mortality among hemodialysis patients remains strikingly high—around 10% per year—despite substantial advances in dialysis technology and medical care. Historically, several strategies extrapolated from the general population have failed to improve outcomes: The landmark 4D and AURORA trials showed no cardiovascular or survival benefit from statin therapy in dialysis patients, whereas high-volume online hemodiafiltration (ESHOL, CONVINCE) significantly reduced all-cause mortality, though without a specific reduction in cardiovascular deaths.
Category
Transplant
Source
Nephrol Ther
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.